# Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction

> **NCT00045318** · PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** exatecan mesylate

## Key facts

- **NCT ID:** NCT00045318
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045318, "Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00045318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*